TVRD Company Profile and Key Details

TVRD has shown mixed momentum, gaining 3.12% over the past week and -29.64% over the past quarter, though year-to-date performance is up 7.67%. Short-term trend indicators are bullishly aligned (SMA20 7.13%, SMA50 -0.68%, SMA200 -76.67%). The stock’s 14-day RSI is 54.62 (neutral), while the ATR of 0.28 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -90.72% below its high and over 15.71% above its low. Average 10-day trading volume of 124.52 thousand shares is below the 3-month average of 2.33 million, indicating normal recent market interest.

Tvardi Therapeutics, Inc. generated EPS of -$9.85 over the past year. Five-year average earnings growth is 12.29%. Wall Street analysts project EPS growth of -21.93% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 5 Buy ratings, 2 Hold ratings, 0 Sell rating and 1 Strong Sell ratings. Price targets range from $61.00 to $3.00. The high target offers 3233.33% upside. The low target suggests 63.93% downside. The mean target is $14.00. This offers 665.03% upside. Tvardi Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended August 13, 2026, missed forecasts by -2.05%. The prior quarter beat by -1.92%. Over the last six quarters, Apple has recorded several small beats. These include 450.43% in May 13, 2025.

Tvardi Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.64. This means the shares are trading below this model’s fair value.

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) shares are flat 7.67% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Tvardi Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.63. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $25.54, suggesting 1295.63% upside. Our AI forecast model points to short-term strength (2.19% over two weeks), a medium-term fall (-67.21% over three months), and a longer-term loss (-83.61% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Tvardi Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.19%, with price expected at $1.87 by September 28, 2026, within a range of $1.77 to $1.97 3-Month Outlook: Projected fall of -67.21%, reaching $0.60 by December 11, 2026, with a range of $0.02 to $1.16. 1-Year Outlook: Projected loss of -83.61%, with price at $0.30 by September 14, 2027, within a range of $0.00 to $0.00.

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) closed at $1.76 USD, losing -$0.07 (-3.83%) from the previous close of $1.83. The stock is currently mid-range between its 52-week high and low $1.50 and $43.65. With a market capitalization of about $16.51 million, Tvardi Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.39). Key stats such as the average daily volume over the past year has been around 2.38 million shares, volume is running light vs its 52-week average. Headquartered in Sugar Land, TX, Tvardi Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Imran Alibhai, the company employs approximately 12 people and listed since January 31, 2014. Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States.

Tvardi Therapeutics, Inc. trades at a P/E ratio of -0.63, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.95 suggesting the stock is closer to book value. The P/FCF stands at -0.66, also above market averages.